Navigation Links
Tissue engineering methods earn funding to heal little hearts
Date:2/18/2011

HOUSTON (Feb. 18, 2011) -Texas Children's Hospital in Houston announces that a researcher in its Pediatric Cardiac Bioengineering Laboratory has earned a National Science Foundation Early Career Development (CAREER) Award for his work in studying the causes of congenital heart disease, heart defects, and the development of tissue engineering therapies using stem cells derived from human amniotic fluid. The award comes with new funding of $450,000 to be spread over a five-year period.

Jeffrey Jacot, Ph.D, director of the Pediatric Cardiac Bioengineering Laboratory at the Congenital Heart Surgery Service at Texas Children's Hospital and an assistant professor of bioengineering at Rice University, submitted work based on two years of previously published studies on the effects of substrate stiffness on maturing heart cells, the mechanical environment of cardiovascular tissues, and the development of heart tissue grown from stem cells taken from the amniotic fluid of patients' mothers. His work with cardiac tissue stems from a 2009 grant from the Virginia and L.E. Simmons Family Foundation Collaborative Research Fund, which promotes research among Texas Medical Center scientists, engineers and doctors who might not otherwise work together.

"I am pleased to be part of the groundbreaking congenital heart research at Texas Children's Hospital," said Dr. Jacot. "We hope this work will lead to the development of living heart tissue that might work to 'patch' or reconstruct hearts with congenital defects."

As a principal investigator on several projects, Jacot works alongside surgeons and radiologists at Texas Children's Hospital and with cardiovascular research laboratories at Baylor College of Medicine (BCM) to establish a therapeutically feasible stem cell source and understand how to control growth of new cardiac tissue.

"Dr. Jacot is a talented and highly inventive young member of the biomedical engineering community whose detailed analysis and rationally designed experiments bring a unique approach to the study and treatment of congenital heart disease," said Charles D. Fraser Jr., M.D., surgeon-in-chief and chief of congenital heart surgery at Texas Children's Hospital and professor of surgery at BCM. "Because the regenerative cardiac therapies developed in his lab are grown from amniotic fluid-derived stem cells, they are genetically identical to the child and have potential to grow with the patient with minimal immune response."

Jacot's CAREER Award also includes an interactive exhibition and outreach program for elementary, middle and high school students to be developed in cooperation with the John P. McGovern Museum of Health and Medical Science (MMHM) in Houston. The educational component, which is intended to inspire and help guide the next generation of scientists and engineers, includes field trips and teacher workshops, as well as lectures and problem-based curriculum in systems physiology at Rice.


'/>"/>

Contact: Carol Wittman
cmwittma@texaschildrens.org
832-824-2040
Texas Children's Hospital
Source:Eurekalert

Related medicine news :

1. New study suggests stem cells sabotage their own DNA to produce new tissues
2. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
3. Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of Stepping to Raise Awareness for Organ and Tissue Donation
4. CSMG Technologies, Inc. Engages New Team to Manage Live Tissue Connect, Inc.
5. Paired drugs kill precancerous colon polyps, spare normal tissue
6. Tissue engineers create a new way to assemble artificial tissues
7. Ultrasound could boost tissue implant success
8. Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue
9. Molecular Signatures in Post-Mortem Brain Tissue of Younger Individuals at High Risk for Alzheimer's Disease
10. Scholar calls for a new legal, ethical framework for research with human tissue specimens
11. New method of tissue banking makes gene analysis more practical for lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: